import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "how-much-does-cagrilintide-cost-research-pricing-guide",
  title: "How Much Does Cagrilintide Cost? Research Pricing Guide (2026)",
  description:
    "A transparent look at cagrilintide pricing in 2026 — per-vial costs, what drives higher prices vs. semaglutide, why it's harder to synthesize, and how to verify vendor quality for this amylin analog. For researchers studying the CagriSema combination.",
  category: "Research Fundamentals",
  readMinutes: 8,
  publishedAt: "2026-06-20",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Cagrilintide is a long-acting amylin analog developed by Novo Nordisk and studied as part of the CagriSema combination (cagrilintide + semaglutide) for metabolic research. Unlike the short peptides populating most of the research market, cagrilintide is a structurally complex modified amylin derivative with multiple non-natural amino acids and a fatty acid side chain for half-life extension. This complexity makes it one of the more expensive peptides available through research suppliers — and one of the most uneven in quality across vendors.",
    },
    {
      type: "heading",
      text: "Typical Cagrilintide Pricing in 2026",
    },
    {
      type: "paragraph",
      text: "Cagrilintide entered the research market in significant volume as interest in the CagriSema combination expanded. Pricing reflects its synthesis difficulty — more analogous to semaglutide and tirzepatide than to simpler GHRPs or tetrapeptides.",
    },
    {
      type: "table",
      headers: ["Vial Size", "Typical Price Range", "Cost per mg (midpoint)", "Notes"],
      rows: [
        ["1 mg", "$55–$90", "~$72.50/mg", "Pilot dose–response research"],
        ["2 mg", "$90–$150", "~$60/mg", "Short-duration metabolic study"],
        ["5 mg", "$180–$290", "~$47/mg", "Standard research vial"],
        ["10 mg", "$300–$500", "~$40/mg", "Extended protocol or multi-experiment"],
      ],
    },
    {
      type: "paragraph",
      text: "These figures reflect pricing from vendors with accessible COA documentation. Significantly lower pricing — for example, 5 mg under $100 — is a strong signal that either the peptide is mislabeled, severely underdosed, or has not been subjected to any independent analytical testing.",
    },
    {
      type: "heading",
      text: "Why Cagrilintide Is More Expensive Than Common Research Peptides",
    },
    {
      type: "subheading",
      text: "Structural Complexity",
    },
    {
      type: "paragraph",
      text: "Amylin (IAPP) itself is a 37-amino acid peptide with an intramolecular disulfide bridge and a C-terminal amide — two modifications that significantly complicate synthesis. Cagrilintide introduces additional non-natural amino acid substitutions that reduce aggregation and extend half-life, plus a C18 fatty diacid side chain similar to those used in semaglutide and liraglutide. These modifications require specialized SPPS conditions, selective side-chain deprotection, and fatty acid conjugation steps that are not part of standard peptide synthesis workflows.",
    },
    {
      type: "subheading",
      text: "Disulfide Bridge Formation",
    },
    {
      type: "paragraph",
      text: "Correct formation and verification of the intramolecular disulfide bond is a critical quality control step. Improperly oxidized cagrilintide — with a scrambled or absent disulfide — will have altered receptor binding and biological activity. Verifying correct disulfide formation requires mass spectrometry under both reducing and non-reducing conditions, adding analytical cost.",
    },
    {
      type: "subheading",
      text: "Fatty Acid Conjugation",
    },
    {
      type: "paragraph",
      text: "The C18 fatty diacid chain responsible for cagrilintide's prolonged half-life is conjugated through a linker at a specific lysine residue. This conjugation step requires orthogonally protected starting materials, specialized coupling chemistry, and HPLC purification to separate correctly conjugated from unconjugated peptide. The yield and purity at this step significantly affects per-unit cost.",
    },
    {
      type: "subheading",
      text: "HPLC Purification Challenges",
    },
    {
      type: "paragraph",
      text: "The lipophilic fatty acid chain makes cagrilintide significantly less water-soluble than typical research peptides, complicating the reverse-phase HPLC purification used to achieve research-grade purity. Longer column runs, higher organic solvent consumption, and lower column loading create higher purification costs per gram of purified compound.",
    },
    {
      type: "heading",
      text: "Cagrilintide vs. Related Metabolic Peptides: Pricing Context",
    },
    {
      type: "table",
      headers: ["Compound", "Typical 5 mg Price", "Key Complexity Factor", "Research Application"],
      rows: [
        ["Cagrilintide", "$180–$290", "Amylin structure + C18 chain + disulfide", "Amylin analog, CagriSema combo"],
        ["Semaglutide", "$80–$150", "GLP-1 analog + C18 chain", "GLP-1 receptor agonism"],
        ["Tirzepatide", "$140–$220", "GIP/GLP-1 dual agonist, 39 AA", "Dual incretin"],
        ["Retatrutide", "$180–$280", "GIP/GLP-1/GCG triple agonist, 39 AA", "Triple agonist"],
        ["Ipamorelin", "$22–$45", "5 AA, straightforward SPPS", "GH secretagogue"],
        ["BPC-157", "$28–$55", "15 AA, no modifications", "Tissue repair research"],
      ],
    },
    {
      type: "paragraph",
      text: "Cagrilintide is priced in the tier of structurally complex, acylated metabolic peptides — below retatrutide but above standard GLP-1 analogs, reflecting its amylin-family structural features.",
    },
    {
      type: "heading",
      text: "Quality Verification for Cagrilintide",
    },
    {
      type: "paragraph",
      text: "Given the structural complexity of cagrilintide, minimal quality verification should include:",
    },
    {
      type: "list",
      items: [
        "HPLC chromatogram showing ≥98% purity under reverse-phase conditions",
        "Mass spectrometry confirming the correct molecular weight (approximately 3,895 Da for cagrilintide)",
        "Disulfide bond confirmation via non-reducing MS conditions",
        "Fatty acid conjugation confirmed — unconjugated 'backbone peptide' should appear as a separate peak if present",
        "Endotoxin (LAL) testing documentation for any in vivo research model",
        "Lot number on the COA matching the vial label",
      ],
    },
    {
      type: "paragraph",
      text: "Vendors who cannot provide an actual HPLC chromatogram with integration values and a mass spectrum with the correct molecular ion for cagrilintide should not be trusted for this compound specifically. The structural verification requirements here are more demanding than for simpler peptides — a fake or degraded product could present as 'peptide-like' on a low-sensitivity assay while having no amylin receptor activity.",
    },
    {
      type: "heading",
      text: "Research Context: Why Researchers Purchase Cagrilintide",
    },
    {
      type: "paragraph",
      text: "Interest in cagrilintide is primarily driven by the clinical data from Novo Nordisk's REDEFINE program, which evaluated the CagriSema combination (cagrilintide 2.4 mg + semaglutide 2.4 mg) against semaglutide monotherapy. Phase 2 data suggested meaningfully greater weight loss with the combination. Preclinical researchers studying metabolic endpoints — adiposity, glucose homeostasis, food intake, GLP-1 and amylin receptor signaling — increasingly want to include an amylin receptor axis alongside GLP-1 pathway research.",
    },
    {
      type: "paragraph",
      text: "Cagrilintide also allows researchers to study amylin receptor pharmacology independently of native amylin's tendency to aggregate and form amyloid fibrils — the same process implicated in type 2 diabetes-related islet pathology. The modifications in cagrilintide reduce this aggregation tendency while preserving receptor binding.",
    },
    {
      type: "heading",
      text: "What to Expect Paying More For",
    },
    {
      type: "paragraph",
      text: "For a compound as complex as cagrilintide, paying within the documented-vendor price range is the minimum threshold for having any confidence in what you are actually working with. The consequences of a mislabeled or degraded product extend beyond wasted money — misinterpretation of biological results from a compromised compound contaminates the research record.",
    },
    {
      type: "heading",
      text: "Where Nexphoria Fits",
    },
    {
      type: "paragraph",
      text: "Nexphoria offers cagrilintide with batch-specific HPLC and mass spectrometry documentation. Pricing reflects the actual synthesis and testing overhead for this structurally complex compound. Researchers evaluating CagriSema protocols or amylin receptor biology will find documentation at the level the science requires.",
    },
    {
      type: "callout",
      text: "Cagrilintide is sold for research purposes only. It is not approved for human use. Researchers should follow all applicable institutional protocols and regulatory guidelines.",
    },
    {
      type: "disclaimer",
      text: "Pricing data reflects market survey information as of mid-2026 and may change. This article is for informational purposes and does not constitute a price guarantee or competitive comparison.",
    },
  ],
};
